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fractions in cervical cancer intracavitary-intersticial MR/CT-
based BT. 
Materials and Methods: 45 consecutive patient cervical 
cancer patients treated between January 2013 and May 2014 
were considered. FIGO stage distribution was the following: 4 
had stage IB, 33 had IIB (7 out of 33 with distal parametrial 
invasion), 7 had IIIB tumors (all because parametrial invasion 
up to pelvic wall) and 1 had IVA tumor. Treatment consisted 
in 3DCRT (45 Gy in 25 fr.) with concomitant chemotherapy 
(weekly cisplatin 40 mg m2) followed by MR/CT based IGABT 
(4 fractions of 7 Gy within 2 insertion with 1 week interval 
with Elekta Utrecht applicator). A stringent bladder filling 
and bowel preparation protocol is routinely used at our 
institution.  
At 1st application, T2 MRI and i.v. contrasted CT (day 1 CT) 
with applicator in place were performed with an interval of 
30 min (MR slice thickness 3,5 mm without gaps; CT thickness 
2mm). Direct applicator reconstruction on MR images was 
performed and dose optimized to target volumes and OAR 
delineated on MR according GEC ESTRO recommendations. 
After patient treatment, original MR and CT datasets were 
fused based on the applicator coordinates and HRCTV 
contours from MR dataset transferred to CT. Further OARs 
were re-delineated on day 1 CT, applicator reconstructed and 
the original MR optimized plan recalculated on CT images. 
DVH parameters for OAR delineated on day1 CT were 
recorded (Intrafraction variability). 
On the following day, a second CT was performed (2mm slice 
thickness). Furthermore day 2 CT was fused with the day 1 
CT on the applicator coordinates and the original MR based 
HRCTV contours (present on CT day 1) transferred from day 1 
CT to day 2 CT. OAR were then delineated on day 2 CT and 
the original MR optimized plan recalculated on CT day 2 
images. DVH parameters for OAR delineated on day 2 CT 
were recorded (interfraction variability). 
We assume in our study design that intra-fraction variability 
is predominantly due to systematic contouring uncertainties 
introduced by OAR delineation on different imaging 
modalities and less importantly by eventual OAR movements. 
We expect that interfraction variability to be of higher 
magnitude and predominantly due to OAR movements. 
Results: Results are summarized in Tab 1. The magnitude of 
intra- and inter-fraction variability is very low probably with 
no clinical relevance in the vast majority of patients. Intra- 
and inter-fraction HRCTV and OAR variability is similar. 
 
 
 
Conclusions: Presented data together with previously 
published reports from Lang S. et al. (R&O 2013) seems to 
suggest that, in a protocol of four fractions within 2 different 
applications no re-planning is needed to safely deliver the 
second BT fraction of each application if an OAR filling 
protocol is applied. Nevertheless before applying this concept 
in the clinical routine more data are warranted. 
 
PO-1015   
High Dose Rate image guided adaptive brachytherapy for 
cervical cancer - a single centre experience 
 
U. McGivern1, M. Byrne2, H. Vennard1, A. Drake1, J. Clarke1, 
G. Workman2 
1Northern Ireland Cancer Centre belfast city hospital, 
Clinical Oncology, Belfast, United Kingdom  
2Northern Ireland Cancer Centre belfast city hospital, 
Medical Physics, Belfast, United Kingdom  
 
Purpose/Objective: To review doses achieved in the 
treatment of locally advanced cervical cancer at the 
Northern Ireland Cancer Centre compared to standards set by 
GEC-ESTRO since the introduction of image guided high dose 
rate brachytherapy.  
To compare outcomes both in terms of recurrence and 
survival and long term toxicity with published outcomes. 
Materials and Methods: Retrospective review of clinical 
notes and radiotherapy prescriptions of all patients with 
locally advanced cervical ca treated at the Northern Ireland 
Cancer Centre from 2008-2013. 
Results: 188 patients with locally advanced cervical cancer 
were treated with radical intent with a median age 47.4 
years (23.3 -79.80.4). Median follow up is 25.5 months. 
180/188 had concurrent cisplatin. CT scanning was carried 
out after each intra-cavity insertion and used to contour OAR 
and to identify Point A. Equivalent doses in 2Gy fractions 
(EQD2) were calculated combining external beam 
radiotherapy and brachytherapy doses. αβ 10 was used for 
tumour and αβ3 used for organs at risk. Median dose to point 
A EQD2 was 76.4Gy (66.5-79.3) with 68 patients receiving less 
than <75Gy. Median dose to rectum was 65.5Gy (57.2-
82.6)with 3 patients receiving more than 75Gy.Median dose 
to bowel was70.7Gy (55.5-79.2) with 26 patients receiving 
over 75Gy.Median dose to bladder was 80.5Gy (551-97.8) with 
3 receiving greater than 95Gy. Pelvic recurrence at 3 years 
was 12.2% with distant metastasis 8.5% . Overall Survival (OS) 
at 3years was 74%. There was a documented pelvic or distant 
recurrence at 3years in 30.8% of node positive patients and 
9.45% of node negative patients(p=0.005). Grade 3/4 late 
bowel and bladder toxicity of 7.9 and 6.3% respectively were 
documented. There were no significant differences in dose 
delivered in those patients who developed bladder or bowel 
toxity compared to those who did not. Mean dose to bowel in 
those who had Grade 3/4 toxicity was 71.2Gy and 70.0Gy 
without (p=0.20). Mean dose to bladder in those with GD3/4 
bladder toxicity was78.9Gy and 79.6Gy without (p=0.81). 
Repeat MRI in the final week of radiotherapy was introduced 
in 2010 and performed in 97 patients. In those who had a 
complete response at final week MRI (30) there was 1 pelvic 
recurrence compared to 22 pelvic recurrences in those who 
had partial response or stable disease(77) (p=.0035).  
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Conclusions: CT guided high dose brachytherapy can be 
successfully implemented in a cancer centre achieving good 
levels of local control and overall survival. Node positivity on 
original MRI is predictive for recurrence.A complete response 
on week 5 MRI predicts for excellent long term pelvic control. 
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Purpose/Objective: To assess self-reported quality of life 
(QoL) experienced by cervical and endometrial cancer 
patients after radiation therapy and in regular follow up. Our 
purpose is to evaluate QoL related to urinary and bowel 
symptoms and sexual functioning in order to identify patient- 
and disease-related influencing factors. 
Materials and Methods: Since March 2011, 48 patients in 
regular follow-up for cervical cancer staged Ib1-IIIB (26 
operated and 22 non -operated) and to 82 patients in follow 
up for endometrial cancer staged IA-IIIC (76 operated and 6 
non -operated) after postoperative or radical pelvic 
radiotherapy ± brachytherapy boost were invited to fill in the 
anonymous EORTC-QLQ30 questionnaire. This questionnaire 
was combined with EN24 in case of endometrial cancer or CX 
24 in case of cervical cancer. Exclusion criteria was the 
inability to understand the questionnaire. There was no 
limitation with regard to age or performance status. We 
analyzed overall health and overall quality of life, bladder 
symptoms, disuria and bladder and faecal incontinence. We 
also analyzed items related to sexual function (sexual 
interest and activity) and sexual symptoms (vaginal dryness).  
Results: Everybody accepted to compile the questionnaire 
and only 5 patients needed some assistance. Most patients 
found that the questions were clear and easy to understand. 
Median age was 62.3 years (range 29–81). With a median 
follow up of 4.5 years (range 1.2-6.5), 78% of women were 
free of disease and 21% had evidence of tumour progression 
or relapse. All items exhibited good compliance with no 
missing values except those regarding sexual function that 
were missed in 37.5% of patients. The 92.5% of women 
judged their overall health and QoL good. In particular all 
patients with no evidence of tumour relapse judged a 
favorable QoL, and only 36% of patients with progression 
disease judged their QoL poor.  
Table 1 shows the answers considering tumour type and 
treatment modality. 
We calculated the Chi-Square Test to compare treatment 
modalities (operated or non-operated patients; pelvic 
external beam radiotherapy ± brachytherapy) and tumour 
sites (cervical or endometrial) for the various items. For all 
the items of Table 1, we did find a trend just below the 
threshold of significance (p=0.06-0.08). 
 
 
 
Conclusions: From our analysis, it emerged a good QoL for 
the whole series with similar percentages for the different 
tumour types and treatment modalities. The presence of 
tumour progression reduced QoL. We found that patients 
treated for cervical cancer complained of higher incidence of 
disuria and bladder incontinence. No patient complained of 
severe symptoms related to gastro-intestinal dysfunction or 
faecal incontinence.  
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